GFCR All Grant Programs
Gateway Traditional Grant Program
Core grants funding early phase clinical trials for cancers of all types at renowned institutions around the world. These grants are typically 2-5 years in duration with award amounts from $200,000 to $1.5 million.
NCI/ SPORE/ P20 Program
Our collaboration with the National Cancer Institute (NCI)/Specialized Programs of Research Excellence (SPORE)/ P20 Program allows us to fund more patient-centric research.
Gateway collaborates with the NCI seeking proposals from SPORE and P20 awardees that could enable principal investigators and their respective institutions to expand a clinical trial by adding an additional arm, adding new patient cohorts to an existing clinical trial, and/or generating new correlative analysis. Funding cannot duplicate the scope of work of the SPORE award.
This grant program will support translational research through clinical trials conducted by institutions that receive NCI SPORE awards. Gateway will issue grant awards based on an application and review process conducted by Gateway.
Integrative Research
Gateway focuses on funding integrative oncology research that pairs conventional therapies with evidence-based, complementary therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life during treatment.
Society for Integrative Oncology (SIO)
Our collaboration with the Society for Integrative Oncology (SIO) allows us to bring the most promising patient-centered, integrative oncology research proposals forward, Gateway collaborates with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership. SIO’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.
Decentralized Clinical Trial Initiative (DCTI)
During the COVID-19 pandemic, we launched a new grant program to fund research leveraging site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients’ doorsteps.
Successful DCTI proposals should:
-
Advance a treatment-based clinical trial in oncology
-
Emphasize the delivery of the investigational treatment in a decentralized setting, ideally home-based
-
Define compelling primary and secondary endpoints
-
Creatively leverage one or more innovative technologies (telemedicine, wearables, remote monitoring, medical record review, e-consent, etc.)
-
Have been reviewed with your CTO Administrative Director for regulatory, data management, and safety considerations related to implementation
-
Integrate mobile clinician management, as needed
-
Incorporate rigorous and methodical collection, management, and analysis of trial-related data
-
Utilize clinical resources in proximity and convenient to patients for any trial-related procedures that cannot practicably be carried out in a decentralized setting (e.g. imaging, interventional radiology, complex infusion, etc.)
-
Leverage strategic inter- and/or intra-institutional collaboration, including commercial (e.g. biopharmaceutical, CRO, home health companies, etc.)